Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Fox Chase Cancer Center

Aug 2008
Fox Chase Cancer Center of Philadelphia and VisEn Medical Inc. of Woburn, Mass., have partnered to advance the Phase I clinical trials of the company’s “smart” fluorescence-activatable imaging agents, which they hope will enable physicians to identify and characterize early-stage disease in oncology patients. The trials initially will focus on ovarian cancer and are scheduled to begin in 2009.

BiophotonicsflourescenceFox Chase Cancer CenterimagingNews & Features

Terms & Conditions Privacy Policy About Us Contact Us
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2019 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x Subscribe to BioPhotonics magazine - FREE!
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.